Stockscreener 앱 받기
2.15
3.59%
-0.08
시간 외 거래:
2.19
0.04
+1.86%
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings - Defense World
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MAIA Biotechnology Inc (MAIA): A New Perspective - Stocks Register
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
MAIAMAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - BioSpace
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Canada
Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock - MarketBeat
Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechno - GuruFocus.com
Director Ramiro Guerrero Acquires 88,534 Shares of MAIA Biotechn - GuruFocus.com
Maia Biotechnology director Steven Chaouki buys $55,553 in shares By Investing.com - Investing.com Australia
Maia Biotechnology director Steven Chaouki buys $55,553 in shares - Investing.com
Maia Biotechnology director Luput acquires shares worth $55,553 By Investing.com - Investing.com Nigeria
Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com
Cosmo Metals Secures $500,000 for Strategic Expansion - MSN
Antipa Minerals Expands Share Offering on ASX - MSN
WAM Alternative Assets Expands ASX Securities Offering - MSN
Argent BioPharma Issues New Shares Amidst Strategic Growth - MSN
MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4%Here's What Happened - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% – Time to Sell? - Defense World
Alterity Therapeutics Prepares for 2024 Annual General Meeting - MSN
Li Bang International announces pricing of initial public offering - MSN
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - BioSpace
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 1.1% - MarketBeat
BioAge, BKV shares end their first trading day flat after earlier gains - MSN
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO - MSN
Healthcare Stock Performance - Yahoo Finance
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE) - Defense World
Promising signs for MAIA’s telomere-targeting treatment - The Pharma Letter
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8% - Defense World
THIO Combo Yields Survival Benefit in Advanced NSCLC - AJMC.com Managed Markets Network
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CAE - PR Newswire
Summit Therapeutics jumps 4%, raises $235M - MSN
MAIA Biotechnology - The Pharma Letter
MAIA Biotechnology Reports Promising Interim Results in Lung Cancer Treatment Study - Vancity Buzz
MAIA Biotechnology Inc’s latest rating changes from various analysts - Knox Daily
MAIA reports survival benefit in advanced lung cancer trial - Investing.com
MAIA Biotech releases Phase II results for THIO - The Pharma Letter
MAIA reports survival benefit in advanced lung cancer trial By Investing.com - Investing.com Australia
MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - StockTitan
MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.9% - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.9% - Defense World
MAIA Biotechnology Inc [MAIA] Investment Guide: What You Need to Know - Knox Daily
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Down 13.9% in August - MarketBeat
Lazertinib With Amivantamab Approved by FDA for Use in NSCLC - AJMC.com Managed Markets Network
Mather Group LLC. Increases Stock Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
32,487 Shares in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Acquired by Virtu Financial LLC - Defense World
Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum - MSN
0.93%
3.55%
자본화:
|
볼륨(24시간):